G-MedTech.com

The multilingual platform for the MedTech industry, with news centre, marketplace, community and consultancy services.

[G-MedTech.com @GMedtech]

Huashan Hospital affiliated with Fudan University has completed the world’s first implant procedure of a brain-computer interface (BCI) hand function system following its market approval, marking the technology’s transition from research to routine clinical care.
https://t.co/F73NjvjQ26

[G-MedTech.com @GMedtech]

Siemens Healthineers has broken ground on a second-phase expansion of its Wuxi R&D and manufacturing base in East China, investing over 100 million yuan to localize production of high-end CT X-ray tubes and high-voltage generators for global supply. https://t.co/CHKxTM114D

[G-MedTech.com @GMedtech]

Mindray Medical plans to issue H-shares and list on the Hong Kong Stock Exchange to strengthen its international capital base, support overseas expansion, and accelerate its global strategy, with completion expected within two years pending regulatory approvals. https://t.co/HJBavHP5Rx

[G-MedTech.com @GMedtech]

Siemens Healthineers CEO Dr. Bernd Montag visited Beijing, Shanghai, and Hangzhou to deepen collaborations, expand R&D, and advance digital health in China.
https://t.co/AyDg6jLC3R

[G-MedTech.com @GMedtech]

Beijing-based FireGen Medical raises over RMB 100 million (US$ 14M) in Series D+ funding to accelerate AI-driven rapid diagnostic systems and expand global market presence.
https://t.co/OFMpuZ0GXi

[G-MedTech.com @GMedtech]

Roche Diagnostics commenced construction on its expanded manufacturing and R&D facility in Suzhou, China, dedicated to diagnostic reagents and medical equipment. https://t.co/KrbUMZnSIM

[G-MedTech.com @GMedtech]

DESKi recebe autorização da FDA para seu software de imagem cardíaca HeartFocus com IA, permitindo que qualquer profissional de saúde realize ecocardiogramas de nível clínico após treinamento mínimo. Ensaios clínicos mostraram 100% de precisão diagnóstica equivalente a sonografistas especializados. https://t.co/w7ylApycDr

[G-MedTech.com @GMedtech]

DESKi receives FDA clearance for HeartFocus AI cardiac imaging software, enabling any healthcare provider to perform clinical-grade echocardiograms after minimal training. Clinical trials showed 100% diagnostic accuracy matching expert sonographers. https://t.co/4GuvqUrh6D

[G-MedTech.com @GMedtech]

DESKi recibe autorización de la FDA para su software de imagen cardíaca HeartFocus con IA, permitiendo que cualquier proveedor de salud realice ecocardiogramas de grado clínico con formación mínima. Los ensayos clínicos mostraron un 100% de precisión diagnóstica equiparable a ecografistas expertos.https://t.co/PWSlQUIIit

[G-MedTech.com @GMedtech]

DESKi receives FDA clearance for HeartFocus AI cardiac imaging software, enabling any healthcare provider to perform clinical-grade echocardiograms after minimal training. Clinical trials showed 100% diagnostic accuracy matching expert sonographers. https://t.co/4GuvqUrh6D

[G-MedTech.com @GMedtech]

DESKiのAI心臓画像ソフトウェアHeartFocusがFDA承認を取得。医療従事者が最小限のトレーニングで臨床レベルの心エコー検査を実施可能に。臨床試験では専門の超音波技師と同等の100％の診断精度を達成。https://t.co/mUcRhVhb7S

[G-MedTech.com @GMedtech]

DESKi receives FDA clearance for HeartFocus AI cardiac imaging software, enabling any healthcare provider to perform clinical-grade echocardiograms after minimal training. Clinical trials showed 100% diagnostic accuracy matching expert sonographers. https://t.co/4GuvqUrh6D

[G-MedTech.com @GMedtech]

DESKi obtient l'approbation de la FDA pour son logiciel d'imagerie cardiaque HeartFocus à IA, permettant à tout professionnel de santé de réaliser des échocardiographies de qualité clinique après une formation minimale. Les essais cliniques ont montré une précision diagnostique de 100% équivalente à celle des échographistes experts.https://t.co/pq8USF0fO1

[G-MedTech.com @GMedtech]

DESKi receives FDA clearance for HeartFocus AI cardiac imaging software, enabling any healthcare provider to perform clinical-grade echocardiograms after minimal training. Clinical trials showed 100% diagnostic accuracy matching expert sonographers. https://t.co/4GuvqUrh6D

[G-MedTech.com @GMedtech]

法国DESKi公司HeartFocus AI心脏成像软件获FDA批准，使任何医疗人员在短暂培训后即可完成临床级超声心动图检查。临床试验显示其诊断准确率与专业超声技师相比达到100%一致。https://t.co/QWV8QDCKeB

[G-MedTech.com @GMedtech]

DESKi receives FDA clearance for HeartFocus AI cardiac imaging software, enabling any healthcare provider to perform clinical-grade echocardiograms after minimal training. Clinical trials showed 100% diagnostic accuracy matching expert sonographers. https://t.co/4GuvqUrh6D

[G-MedTech.com @GMedtech]

DESKi erhält FDA-Zulassung für die KI-Software HeartFocus zur Herz-Bildgebung, die es jedem medizinischen Fachpersonal ermöglicht, klinisch hochwertige Echokardiogramme nach minimaler Schulung durchzuführen. Klinische Studien zeigten 100%ige diagnostische Genauigkeit im Vergleich zu Experten-Sonographen.https://t.co/vDcAQJvI56

[G-MedTech.com @GMedtech]

DESKi receives FDA clearance for HeartFocus AI cardiac imaging software, enabling any healthcare provider to perform clinical-grade echocardiograms after minimal training. Clinical trials showed 100% diagnostic accuracy matching expert sonographers. https://t.co/4GuvqUrh6D

[G-MedTech.com @GMedtech]

DESKi receives FDA clearance for HeartFocus AI cardiac imaging software, enabling any healthcare provider to perform clinical-grade echocardiograms after minimal training. Clinical trials showed 100% diagnostic accuracy matching expert sonographers. https://t.co/4GuvqUrh6D

[G-MedTech.com @GMedtech]

Edwards Lifesciences O SAPIEN M3 torna-se o primeiro sistema de substituição valvar mitral transfemoral aprovado pela CE, oferecendo nova opção de tratamento para pacientes com insuficiência mitral inoperável. https://t.co/TtZGgmLV5C

[G-MedTech.com @GMedtech]

Edwards Lifesciences SAPIEN M3 becomes first CE-approved transfemoral mitral valve replacement system, offering new treatment option for inoperable mitral regurgitation patients.
https://t.co/bVtqhQpmGT

[G-MedTech.com @GMedtech]

Edwards Lifesciences El SAPIEN M3 se convierte en el primer sistema de reemplazo valvular mitral transfemoral aprobado CE, ofreciendo una nueva opción de tratamiento para pacientes con insuficiencia mitral inoperable. https://t.co/AVAE3ncxSJ

[G-MedTech.com @GMedtech]

Edwards Lifesciences SAPIEN M3 becomes first CE-approved transfemoral mitral valve replacement system, offering new treatment option for inoperable mitral regurgitation patients.
https://t.co/bVtqhQpmGT

[G-MedTech.com @GMedtech]

SAPIEN M3は、CE承認を受けた初の経大腿的僧帽弁置換システムとなり、手術不能な僧帽弁逆流症患者に新たな治療選択肢を提供。 https://t.co/0O8eSdWQC7

[G-MedTech.com @GMedtech]

Edwards Lifesciences SAPIEN M3 becomes first CE-approved transfemoral mitral valve replacement system, offering new treatment option for inoperable mitral regurgitation patients.
https://t.co/bVtqhQpmGT

[G-MedTech.com @GMedtech]

Edwards Lifesciences Le SAPIEN M3 devient le premier système de remplacement valvulaire mitral transfémoral approuvé CE, offrant une nouvelle option thérapeutique pour les patients inopérables atteints d’insuffisance mitrale. https://t.co/tJbSjeVP77

[G-MedTech.com @GMedtech]

Edwards Lifesciences SAPIEN M3 becomes first CE-approved transfemoral mitral valve replacement system, offering new treatment option for inoperable mitral regurgitation patients.
https://t.co/bVtqhQpmGT

[G-MedTech.com @GMedtech]

爱德华生命科学公司SAPIEN M3成为首个获CE认证的经股二尖瓣置换系统，为无法手术的二尖瓣反流患者提供新治疗选择。https://t.co/fbxQ05i17n

[G-MedTech.com @GMedtech]

Edwards Lifesciences SAPIEN M3 becomes first CE-approved transfemoral mitral valve replacement system, offering new treatment option for inoperable mitral regurgitation patients.
https://t.co/bVtqhQpmGT

[G-MedTech.com @GMedtech]

Edwards Lifesciences SAPIEN M3 ist das erste CE-zertifizierte transfemorale Mitralklappen-Ersatzsystem und bietet eine neue Behandlungsoption für Patienten mit nicht-operabler Mitralklappeninsuffizienz. https://t.co/cBLOB0zIYj

[G-MedTech.com @GMedtech]

Edwards Lifesciences SAPIEN M3 becomes first CE-approved transfemoral mitral valve replacement system, offering new treatment option for inoperable mitral regurgitation patients.
https://t.co/bVtqhQpmGT

[G-MedTech.com @GMedtech]

Edwards Lifesciences SAPIEN M3 becomes first CE-approved transfemoral mitral valve replacement system, offering new treatment option for inoperable mitral regurgitation patients.
https://t.co/bVtqhQpmGT